Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MV-012-968 in Healthy Adults
NCT04227210Phase 1Completed
- Sponsor
- Meissa Vaccines
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MV-012-968 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Meissa Vaccines. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 2 more. Started Jan 2020; status: completed.
02
Drugs
MV-012-968
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04227210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227210.